STOPNASH Meeting

停止会议

• 批准号: 8986466
• 负责人: MIRIAM B. VOS
• 金额: $ 2万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-07-01 至 2016-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8986466
• 关键词: Address; Adipocytes; Adult; Affect; American; Area; Attention; Cardiology; Cardiovascular Diseases; Child; Childhood; Clinical; Collaborations; Communities; Consensus; Diagnosis; Disease; District of Columbia; Endocrinologist; Endocrinology; Environment; Epidemic; Family; Fibrosis; Functional disorder; Gastroenterology; Health; Hepatocyte; Hepatology; Hispanics; Incidence; Inflammation; Insulin Resistance; Knowledge; Lead; Lipids; Liver; Liver diseases; Metabolic; Metabolism; Mission; Names; National Institute of Diabetes and Digestive and Kidney Diseases; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Onset of illness; Outcome; Participant; Pathway interactions; Patients; Pattern; Population; Prevalence; Prevention; Public Health; Research; Research Personnel; Science; Scientist; Societies; Staging; Time; Training; United States; Washington; Woman; Work; chronic liver disease; design; diabetes risk; disorder prevention; experience; high risk; improved; interest; meetings; non-alcoholic fatty liver; nonalcoholic steatohepatitis; nutrition; programs; public health relevance; symposium

 DESCRIPTION (provided by applicant): Nonalcoholic fatty liver disease is a chronic liver disease that affects an estimated 10% of the US population including 7 million children. The latest studies on prevalence suggest that the incidence of NAFLD is still rising despite the slowing of the obesity epidemic. Children and adults with NAFLD are at high risk of progressing to end stage liver disease over time and the pathophysiology of NAFLD appears to dramatically increase the risk of diabetes and cardiovascular disease. Because of this and the whole body metabolic dysregulation associated with NAFLD, the research on NAFLD is progressing in many different areas including by pediatric hepatologists, endocrinologists, cardiology, metabolism experts, nutrition scientists, experts in insulin resistance, hepatocyte functions, and adipocyte effects to name just a few. The global aims of this symposium is to bring together experts from diverse fields to move NAFLD research forward, to develop consensus regarding priorities in NAFLD research and to encourage young investigators and investigators from diverse backgrounds to study NAFLD. In order to accomplish these important aims, the "STOPNASH: Symposium on The Origins and Pathways of NASH: Is it Preventable?" one day symposium will be held on October 7th, 2015 at the Washington Hilton, Washington DC in conjunction with the annual meeting of the North American Society of Pediatric Hepatology, Gastroenterology and Nutrition. The overarching theme of this research conference is "what causes the initiation of NASH?" There will be five modules including 1) Clinical patterns informing pathophysiology 2) Systemic metabolic dysregulation associated with NASH 3) Initiation mechanisms of inflammation and fibrosis 4) Research informing prevention and 5) Future research priorities. There will be breakout sessions to promote discussion amongst the researchers and to generate consensus on the most important gaps in research knowledge. Of the 20 experts invited to speak, 8 are women, 2 are Hispanic, and 4 are young investigators. Moderators include 5 young investigators, 3 Hispanic investigators and 50% women. Trainees and young investigators attending will be encouraged to participate in the break-out sessions to discuss research gaps and opportunities. The symposium focuses on a research area that has not been addressed previously in a conference of this type and will provide an excellent training environment for junior investigators interested in pursuing research in NAFLD. We anticipate 150 or more attendees to participate in this unique symposium designed to catalyze the field of NAFLD research, particularly in the area of the onset of the disease. This is expected to lead to synergistic collaborations advancing knowledge to improve outcomes for patients diagnosed with NAFLD in childhood and eventually to promote effective prevention of the disease.

 描述（由申请人提供）： 非酒精性脂肪肝病是一种慢性肝病，估计影响了美国人口的10％，其中包括700万儿童。关于患病率的最新研究表明，NAFLD的事件仍在肥胖流行的速度下降。随着时间的流逝，患有NAFLD的儿童和成年人处于发展为末期肝病的高风险，NAFLD的病理生理学似乎显着增加了糖尿病和心血管疾病的风险。因此，与NAFLD相关的整个身体代谢失调，NAFLD的研究在许多不同的领域都在进行，包括儿科肝病学家，内分泌学家，心脏病学，代谢专家，营养科学家，胰岛素抵抗，肝细胞功能以及脂肪细胞功能以及几个命名的胰岛细胞功能以及一定的效果。 NAFLD研究的前进，要在NAFLD研究中建立有关优先级的共识，并鼓励来自潜水员背景的年轻研究人员和研究人员研究NAFLD。为了实现这些重要目标，“ Stopnash：关于纳什的起源和途径的研讨会：是否可以预防？”一天研讨会将于2015年10月7日在华盛顿特区华盛顿特区举行，并与北美儿科肝，胃肠病学和营养学会的年度会议一起举行。这次研究会议的总体主题是“是什么导致纳什的倡议？”将有五个模块，包括1）临床模式，告知病理生理学2）与NASH相关的全身代谢失调3）感染和纤维化的起始机制4）研究告知预防和5）未来的研究优先级。将会举行突破性的会议，以促进研究人员之间的讨论，并就研究知识中最重要的差距产生共识。在被邀请讲话的20位专家中，有8名是女性，其中2名是西班牙裔，其中4名是年轻的调查员。主持人包括5名年轻调查员，3名西班牙裔调查人员和50％的女性。鼓励参加的学员和年轻的调查人员参加分手会议，讨论研究差距和机会。研讨会的重点是以前在此类会议上没有解决的研究领域，并将为初级调查人员提供出色的培训环境 有兴趣在NAFLD进行研究。我们预计，有150名或更多的参与者参加了这场独特的​​研讨会，旨在促进NAFLD研究领域，尤其是在疾病发作领域。预计这将导致协同合作提高知识，以改善诊断为NAFLD童年时期的患者的结局，并最终促进有效预防该疾病。

项目成果

Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease.

• DOI: 10.1053/j.gastro.2019.08.048
• 发表时间: 2019-12
• 期刊: Gastroenterology
• 影响因子: 29.4
• 作者: Vos MB;Dimick-Santos L;Mehta R;Omokaro SO;Taminiau J;Schabel E;Kleiner DE;Szitanyi P;Socha P;Schwimmer JB;Noviello S;Silberg DG;Torstenson R;Miller V;Lavine JE;Liver Forum Pediatric Working Group
• 通讯作者: Liver Forum Pediatric Working Group